Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Randomized comparison of intranasal and transdermal estradiol
Autore:
Lopes, P; Merkus, HMWM; Nauman, J; Bruschi, F; Foidart, JM; Calaf, J;
Indirizzi:
Women & Childrens Hosp, Serv Gynecol Obstet, F-44093 Nantes 1, France Women & Childrens Hosp Nantes France 1 Obstet, F-44093 Nantes 1, France St Radboud Hosp, Nijmegen, Netherlands St Radboud Hosp Nijmegen Netherlands adboud Hosp, Nijmegen, Netherlands Univ Med Sch, Warsaw, Poland Univ Med Sch Warsaw PolandUniv Med Sch, Warsaw, Poland Univ Milan, Milan, Italy Univ Milan Milan ItalyUniv Milan, Milan, Italy Ctr Hosp Reg Citadelle, Liege, Belgium Ctr Hosp Reg Citadelle Liege Belgium Hosp Reg Citadelle, Liege, Belgium Santa Creu & St Pau Hosp, Barcelona, Spain Santa Creu & St Pau Hosp Barcelona Spain St Pau Hosp, Barcelona, Spain
Titolo Testata:
OBSTETRICS AND GYNECOLOGY
fascicolo: 6, volume: 96, anno: 2000,
pagine: 906 - 912
SICI:
0029-7844(200012)96:6<906:RCOIAT>2.0.ZU;2-N
Fonte:
ISI
Lingua:
ENG
Soggetto:
ESTROGEN-REPLACEMENT THERAPY; POSTMENOPAUSAL WOMEN; EFFICACY; DISEASE; 17-BETA-ESTRADIOL; ACCEPTABILITY; SYMPTOMS; PATCH; LIFE;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Lopes, P Women & Childrens Hosp, Serv Gynecol Obstet, 7 Quai Moncousu, F-44093 Nantes 1, France Women & Childrens Hosp 7 Quai Moncousu Nantes France1 1, France
Citazione:
P. Lopes et al., "Randomized comparison of intranasal and transdermal estradiol", OBSTET GYN, 96(6), 2000, pp. 906-912

Abstract

Objective: To compare the efficacy and patient acceptability of intranasalversus transdermal 17 beta -estradiol (E2) delivery systems for postmenopausal symptoms. Methods: Postmenopausal women were randomly assigned to intranasal 17 beta-E2, 300 mug daily (n = 176) or transdermal 17 beta -E2 (delivering 50 mug/day), two patches per week (n = 185) for 12 weeks, followed by a 4-week period with the alternate treatment. Efficacy was compared between groups using the Kupperman Index and vasomotor symptoms at week 12. Patient acceptability was compared by patient choice of administration route and by questionnaire at week 16. Results: Intranasal and transdermal therapy produced significant reductions in the Kupperman Index and in the occurrence of hot flushes and night sweats at week 12. Alleviation of climacteric symptoms was statistically equivalent in the two treatment groups (P <.001). The difference between groups in the Kupperman Index score of -0.5 +/- 0.9 (95% confidence interval -2.3,1.3) was rvithin the predetermined interval of equivalence. Both therapieswere well tolerated with similar adverse event rates, except for moderate and severe mastalgia which was significantly less frequent with intranasal E2 (7.2%) than with the patch (15.5%, P =.02). Sixty-six percent of patients chose to continue the intranasal therapy and 34% the transdermal therapy (P <.001). Satisfaction was greater with intranasal therapy at week 16 (P <.001). Conclusion: Intranasal and transdermal estrogen delivery systems had equivalent efficacy and similar safety profiles. Intranasal therapy was the patients' choice for long-term treatment. (Obstet Gynecol 2000;96:906-12. (C) 2000 by The American College of Obstetricians and Gynecologists.).

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 25/11/20 alle ore 04:24:05